



PRODUCT: **TUKYSA**

COMPANY: Seagen

THERAPEUTIC AREA & INDICATION:
Treatment of breast cancer

ABOUT THE PRODUCT

TUKYSA® (tucatinib) is an oral medicine approved by the U.S. Food and Drug Administration (FDA) for use in combination with trastuzumab and capecitabine, for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

TUKYSA became the first new therapy approved under the FDA's Project Orbis, which facilitates concurrent international regulatory review of oncology therapies to expedite access for patients. TUKYSA is now approved in 37 countries.